DAK HEALTH has floated a tender for Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Infusion Solution Concentrate), Atc L04aa23 for the Period December 1St, 2023-Novembe.... The project location is Germany and the tender is closing on 05 Oct 2025. The tender notice number is -, while the TOT Ref Number is 91049605. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : Germany

Summary : Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Natalizumab (Exclusively in the Dafo Infusion Solution Concentrate), Atc L04aa23 for the Period December 1St, 2023-Novembe...

Deadline : 05 Oct 2025

Other Information

Notice Type : Tender

TOT Ref.No.: 91049605

Document Ref. No. : Login to see details

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : EUR 1.00

Purchaser's Detail

Name : Login to see details

Address : Login to see details

Email : Login to see details

  Login to see details

Documents

 Tender Notice


Procurement Documents for Germany

Access a comprehensive library of standard procurement documents specific to Germany. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in Germany

Explore Procurement Documents for Germany


Want To Bid in This Tender?

Get Local Agent Support in Germany and 60 More Countries.

View All The Services


View Tenders By


Publish Tenders


Have Any Dispute With The Purchaser?